Zeteo Tech, Inc., Sykesville, Maryland, USA
https://www.zeteotech.com/ 

Zeteo Tech, Inc. is executing a workplan for its noninvasive diagnostic platform that aims to evaluate whether exhaled breath can diagnose lower respiratory tract infections (LRTIs) in high-risk populations within critical care environments, including intubated patients with mechanical ventilation. The Zeteo technology aims to expedite the diagnosis of LRTIs and guide treatment strategies by employing a highly multiplexed, cost-effective MALDI-MS assay to differentiate active infection from colonization, assess antibiotic susceptibility, and distinguish between viral and bacterial infections.

By leveraging these findings, physicians may be able to minimize unnecessary antibiotic administration and facilitate more effective treatment of antibiotic-resistant bacteria. CARB-X funding for this project will explore utilizing breath samples from children as viable alternatives to bronchoalveolar lavage (BAL) or sputum collection, thereby making sample collective less invasive than traditional methods.

Current Development Stage: Seed award

CARB-X Investment: US$1 million

Initial CARB-X Investment Date: September 3, 2025